JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

VolitionRX Ltd

Uždarymo kaina

0.62 1.64

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.53

Max

0.63

Pagrindiniai rodikliai

By Trading Economics

Pajamos

381K

-5.5M

Pardavimai

55K

246K

Pelnas, tenkantis vienai akcijai

-0.06

Pelno marža

-2,222.792

Darbuotojai

82

EBITDA

369K

-5.1M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+329.69% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-13

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

26M

76M

Ankstesnė atidarymo kaina

-1.02

Ankstesnė uždarymo kaina

0.62

VolitionRX Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-04 21:42; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025-08-04 21:21; UTC

Uždarbis
Pagrindinės rinkos jėgos

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025-08-04 20:45; UTC

Uždarbis

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025-08-04 19:15; UTC

Pagrindinės rinkos jėgos

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025-08-04 23:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-04 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Fed Stimulus Hopes

2025-08-04 23:28; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-08-04 23:28; UTC

Rinkos pokalbiai

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025-08-04 21:30; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 21:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025-08-04 21:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 20:25; UTC

Rinkos pokalbiai

India Hits Back Over Russian Oil Purchases -- Market Talk

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss $938M >RIG

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss/Shr $1.06 >RIG

2025-08-04 20:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025-08-04 20:15; UTC

Uždarbis

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025-08-04 20:13; UTC

Uždarbis

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025-08-04 20:09; UTC

Uždarbis

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025-08-04 20:06; UTC

Uždarbis

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025-08-04 19:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025-08-04 19:28; UTC

Rinkos pokalbiai

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025-08-04 19:07; UTC

Rinkos pokalbiai

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025-08-04 18:27; UTC

Rinkos pokalbiai

Gold Climbs on Rate Cut Speculation -- Market Talk

Akcijų palyginimas

Kainos pokytis

VolitionRX Ltd Prognozė

Kainos tikslas

By TipRanks

329.69% į viršų

12 mėnesių prognozė

Vidutinis 2.75 USD  329.69%

Aukščiausias 3 USD

Žemiausias 2.5 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines VolitionRX Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.